<DOC>
<DOCNO>EP-0657430</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate
</INVENTION-TITLE>
<CLASSIFICATIONS>C07C25500	C07D21190	A61P2526	A61P2528	A61K3145	A61K31455	C07D21100	A61P908	C07C25556	A61K3144	A61K31455	A61P900	A61P2500	A61K3144	A61P2524	A61K3145	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07C	C07D	A61P	A61P	A61K	A61K	C07D	A61P	C07C	A61K	A61K	A61P	A61P	A61K	A61P	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07C255	C07D211	A61P25	A61P25	A61K31	A61K31	C07D211	A61P9	C07C255	A61K31	A61K31	A61P9	A61P25	A61K31	A61P25	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention relates to the compound rac-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyanophenyl)-1,4-dihydro-2,6-dimethylpyridine-3,5-dicarb oxylate and its pure enantiomers, to processes for the preparation thereof and to the use thereof as pharmaceutical, in particular for treatment of cerebral and neuronal disorders and to an intermediate for the preparation thereof.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
BAYER AG
</APPLICANT-NAME>
<APPLICANT-NAME>
BAYER AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DE JONG MAARTEN DR
</INVENTOR-NAME>
<INVENTOR-NAME>
GAO ZHAN DR
</INVENTOR-NAME>
<INVENTOR-NAME>
HARTWIG WOLFGANG DR
</INVENTOR-NAME>
<INVENTOR-NAME>
JUNGE BODO DR
</INVENTOR-NAME>
<INVENTOR-NAME>
MEIER HEINRICH DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHMIDT BERNARD DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHOHE-LOOP RUDOLF DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHUURMAN TEUNIS DR
</INVENTOR-NAME>
<INVENTOR-NAME>
DE JONG, MAARTEN DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
GAO, ZHAN DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
HARTWIG, WOLFGANG DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
JUNGE, BODO DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
MEIER, HEINRICH DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHMIDT, BERNARD DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHOHE-LOOP, RUDOLF DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHUURMAN, TEUNIS DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyanophenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
as a racemate and its enantiomeric

forms.
Process for the preparation of the compound
according to Claim 1, characterized in that


[A] 2-chloro-3-cyano-benzaldehyde of the formula

(II)


is reacted first with 2-methoxyethyl acetoacetate of
the formula (III)


H
3
C-CO-CH
2
-CO
2
(CH
2
)
2
OCH
3

if appropriate with isolation of the corresponding
ylidene compound of the formula (IV) 



and subsequently with isopropyl acetoacetate of the
formula (V)


CH
3
-CO-CH
2
-CO
2
-CH(CH
3
)
2

and with ammonia or ammonium salts,

or directly with the isopropyl amino-2-butenoate
which can be prepared from ammonia and (V), of the

formula (VI)


in inert solvents,

or
[B] 2-chloro-3-cyano-benzaldehyde of the formula

(II) is reacted first with the compound of the
formula (V), if appropriate with isolation of

the ylidene compound of the formula (VII) 


and in a next step with the compound of the formula
(III) and with ammonia or ammonium salts or directly

with the 2-methoxyethyl amino-2-butenoate which can
be prepared from ammonia and (III), of the formula

(VIII)


in inert solvents,

or
[C] compounds of the general formula (IX)



in which 

A
represents the radical of the formula -CH(CH
3
)
2

or - (CH
2
)
2
-OCH
3
,

are reacted in inert solvents, if appropriate in the
presence of a base, with auxiliaries to give activated

carboxylic acid derivatives, which are optionally
isolated, and then reacted with alcohols of the

formula (X)

E-OH

in which

E
depending on the definition of the substituent A,
either represents the

-CH(CH
3
)
2
- or -(CH
2
)
2
-OCH
3
-group,

if appropriate after conversion to the alkoxide
using an inorganic base,

and for the preparation of the enantiomers, the
appropriate optically active carboxylic acid derivatives

are reacted with the appropriate alcohols, or

the racemate is separated by chromatography on
chiral stationary phases.
Medicament containing a compound according to Claim
1.
Process for the production of medicaments, characterized
in that a compound according to Claim 1 is

converted into a suitable administration form, if
appropriate using customary auxiliaries and

excipients.
Use of the compounds according to Claim 1 for the
production of a medicament for the control of disorders. 
Use of the compound according to Claim 1 in the
production of medicaments for the control of

neuronal and cerebral disorders.
2-chloro-3-cyano-benzaldehyde.
Process for the preparation of 2-chloro-3-cyanobenzaldehyde,
characterized in that 2-chloro-3-cyano-toluene

is reacted in the presence of a
brominating agent and of a catalyst in inert

solvents to give the corresponding benzal bromide,
and this is reacted in solvents in the presence of

silver salt to give the aldehyde.
</CLAIMS>
</TEXT>
</DOC>
